hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06331416, orgStudyIdInfo id: 208_2022H, briefTitle: One-device Multiparametric Home Telemonitoring of Patients With Chronic Obstructive Pulmonary Disease Exacerbation, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2026-04-01, completionDateStruct date: 2026-09-30, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: University of Trieste, class: OTHER, descriptionModule briefSummary: Chronic obstructive pulmonary disease (COPD) exacerbations are risk factors for disease progression and short-term re- hospitalizations. We propose a randomized controlled trial to evaluate the efficacy of a one-device multiparameter telemonitoring in reducing functional decline, symptoms, and risk of re-hospitalization of patients discharged after hospitalization for exacerbated COPD., conditionsModule conditions: COPD, conditions: COPD Exacerbation Acute, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Open-label randomized controlled trial, allocation ratio 1:1, primaryPurpose: HEALTH_SERVICES_RESEARCH, maskingInfo masking: NONE, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Telemonitoring, outcomesModule primaryOutcomes measure: Re-hospitalization at 90 days, secondaryOutcomes measure: Re-hospitalization at 30 days, secondaryOutcomes measure: Functional decline, secondaryOutcomes measure: Unplanned medical evaluations, secondaryOutcomes measure: Need for mechanical ventilation at 30 days, secondaryOutcomes measure: Need for mechanical ventilation at 90 days, secondaryOutcomes measure: Satisfaction score, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 90 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06331403, orgStudyIdInfo id: 24-009, briefTitle: Open Pilot Trial of a Mind-Body Sexual Well-Being Intervention for Female GI Cancer Survivors, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2025-04, completionDateStruct date: 2025-04, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: Massachusetts General Hospital, class: OTHER, collaborators name: Harvard Medical School (HMS and HSDM), descriptionModule briefSummary: The primary goal of this protocol is to conduct an open pilot to collect initial quantitative and qualitative feedback on the intervention that the investigators are developing. To do so, the investigators will deliver a newly-developed intervention to up to 2 consecutive groups of female colorectal and anal cancer survivors (n = up to 10 per group, total N = up to 20). Participants will provide feedback regarding intervention acceptability, feasibility, and perceived benefit.To inform plans for ongoing program refinement, the investigators will elicit specific feedback about study assessment tools, recruitment procedures, and group factors. Given the early-stage, open pilot nature of this protocol, the investigators will not set strict criteria to establish feasibility and acceptability but will rather interpret each of these outcomes holistically. Qualitative feedback collected in post-intervention exit interviews will also support understanding of feasibility and acceptability.As a secondary aim, the investigators will explore the preliminary effects of the intervention on psychosocial measures of satisfaction with sexuality and impact of functional limitations, coping abilities, acceptance of body image changes, loneliness, and anticipated stigma. As noted above, the investigators will not set specific criteria to establish preliminary efficacy, nor will they consider statistical significance as an indicator of the study's efficacy for these outcomes. Instead, the investigators will consider pre-post intervention effect sizes to consider the need for refinement of study procedures/measurement in a future larger trial.In future, larger-scale, work, the investigators intend to conduct a larger randomized pilot trial to assess intervention acceptability, feasibility, as well as preliminary efficacy on essential outcomes related to sexual well-being., conditionsModule conditions: Colorectal Cancer, conditions: Anal Cancer, conditions: Sexual Dysfunction, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Mind-Body Group Intervention, outcomesModule primaryOutcomes measure: Feasibility of Intervention, primaryOutcomes measure: Acceptability of Intervention, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06331390, orgStudyIdInfo id: 2181-198-03-04-24-0008, briefTitle: Assessment of Niacinamide Cosmetic Product Efficacy in Model of Irritant Contact Dermatitis, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2024-06, completionDateStruct date: 2024-07, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: University of Split, School of Medicine, class: OTHER, descriptionModule briefSummary: Testing the effectiveness and safety of cosmetics with niacinamide in irritant contact dermatitis: A Randomised, Controlled Trial will be conducted at USSM. Healthy volunteers will be included (at least 25) and test sites are forearms. Sodium lauryl sulphate will be used to induce contact dermatitis and participants will be measured for 7 days, conditionsModule conditions: Contact Dermatitis, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: INVESTIGATOR, enrollmentInfo count: 25, type: ESTIMATED, armsInterventionsModule interventions name: niacinamide cosmetic product, interventions name: placebo, outcomesModule primaryOutcomes measure: tewameter, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule locations facility: University of Split School of Medicine, status: RECRUITING, city: Split, country: Croatia, contacts name: Josipa Bukic, role: CONTACT, phone: 00385917933752, email: jbukic@mefst.hr, geoPoint lat: 43.50891, lon: 16.43915, hasResults: False
protocolSection identificationModule nctId: NCT06331377, orgStudyIdInfo id: 17-004541, secondaryIdInfos id: NCI-2024-01765, type: REGISTRY, domain: CTRP (Clinical Trial Reporting Program), secondaryIdInfos id: 17-004541, type: OTHER, domain: Mayo Clinic Institutional Review Board, briefTitle: Clinical and Molecular Characteristics of Histiocytic Disorders, statusModule overallStatus: RECRUITING, startDateStruct date: 2017-07-27, primaryCompletionDateStruct date: 2027-07-31, completionDateStruct date: 2027-07-31, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: Mayo Clinic, class: OTHER, descriptionModule briefSummary: This study is being done to collect medical and personal histories as well as a samples of blood, other body fluid and/or tumor/disease tissue for current and future research studies on histiocytic disorders., conditionsModule conditions: Histiocytic Disorder, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: OTHER, enrollmentInfo count: 500, type: ESTIMATED, armsInterventionsModule interventions name: Non-Interventional Study, outcomesModule primaryOutcomes measure: Identify molecular markers, primaryOutcomes measure: Change in PD-L1 and T-cell Bim expression, eligibilityModule sex: ALL, minimumAge: 1 Year, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Mayo Clinic in Rochester, status: RECRUITING, city: Rochester, state: Minnesota, zip: 55905, country: United States, contacts name: Clinical Trials Referral Office, role: CONTACT, phone: 855-776-0015, email: mayocliniccancerstudies@mayo.edu, contacts name: Ronald S. Go, M.D., role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 44.02163, lon: -92.4699, hasResults: False
protocolSection identificationModule nctId: NCT06331351, orgStudyIdInfo id: A11203001, briefTitle: Effect of Jing Si Herbal Tea Liquid Packets on Chronic Pharyngolaryngitis, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-22, primaryCompletionDateStruct date: 2025-10-31, completionDateStruct date: 2025-12-31, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: Dalin Tzu Chi General Hospital, class: OTHER, descriptionModule briefSummary: Chronic pharyngolaryngitis is common and often make people suffer in many aspects. The etiology is numerous, for example, airway hypersensitivity, gastroesophageal acid regurgitation, sicca syndrome, anxiety, etc.The investigators aimed to investigate the effect of Jing Si herbal tea liquid packets on chronic pharyngolaryngitis by a design of randomized, double-blind clinical trial in this study. The subjects who were bed-ridden, without self-care ability, receiving hemodialysis, no idea about the details of this study, poor compliance for this study, alcohol and/or drugs additives, pregnancy and breast-feeding women were excluded from this study.A questionnaire for health and habits was performed at the start of the study, and a questionnaire for Reflux Symptom Index (RSI) was performed at the start and the end of the study. Finally, Student's t-test was used to test the difference between the Jing Si herbal tea group and the control group. And, multivariate linear regression was used to test the violation of clinical factors on the treatment outcome of Jing Si herbal tea liquid packets on chronic pharyngolaryngitis., conditionsModule conditions: Chronic Pharyngitis, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: OTHER, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, enrollmentInfo count: 120, type: ESTIMATED, armsInterventionsModule interventions name: control group, interventions name: Jing Si herbal tea liquid packets, outcomesModule primaryOutcomes measure: Health questionnaire, primaryOutcomes measure: Reflux Symptom Index (RSI), eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, status: RECRUITING, city: Chiayi City, zip: 66247, country: Taiwan, contacts name: Juen-Haur Hwang, MD, PhD, role: CONTACT, phone: +886-5-2648000, phoneExt: 5239, email: g120796@tzuchi.com.tw, geoPoint lat: 23.47917, lon: 120.44889, hasResults: False
protocolSection identificationModule nctId: NCT06331338, orgStudyIdInfo id: 202310085RIND, briefTitle: Effects of Using Decision Cycle for Person-Centered Glycemic Management in Type 2 Diabetes, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-14, primaryCompletionDateStruct date: 2024-10-31, completionDateStruct date: 2025-12-31, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: National Taiwan University Hospital, class: OTHER, descriptionModule briefSummary: Decision cycle for person-centered glycemic management is a new diabetes decision making .It is defined as a purposefully designed holistic care intervention .The goal is to improve the self-care behavior of patients with type 2 diabetes, thereby improving glycated hemoglobin levels and delaying the occurrence of complications., conditionsModule conditions: Type 2 Diabetes, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: OTHER, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 130, type: ESTIMATED, armsInterventionsModule interventions name: Decision Cycle for Person-Centered Glycemic Management, interventions name: Traditional diabetes self-management education, outcomesModule primaryOutcomes measure: glycemic control (HbA1c), secondaryOutcomes measure: Diabetes Self-Care Behavior Scale, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: National Taiwan University Hospital, status: RECRUITING, city: Hsinchu, zip: 302, country: Taiwan, contacts name: Chia-Hui Tsai, role: CONTACT, phone: 886926124093, email: mtsai0322@gmail.com, geoPoint lat: 24.80361, lon: 120.96861, hasResults: False
protocolSection identificationModule nctId: NCT06331325, orgStudyIdInfo id: 724, briefTitle: Comparison of Frenotomy and Frenectomy Techniques for Management of High Frenum Attachment in Adults, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-20, primaryCompletionDateStruct date: 2024-09-30, completionDateStruct date: 2024-09-30, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: October University for Modern Sciences and Arts, class: OTHER, descriptionModule briefSummary: The goal of this randomized clinical trial is to compare frenotomy to frenectomy surgical techniques in the management of high frenum attachment in adults. The main questions it aims to answer are:* Does Frenotomy procedure have a lower relapse rate compared to frenectomy?* Does Frenotomy procedure result in fewer postoperative complications? Participants will be divided into two groups. The intervention group will involve frenotomy procedure for participants and will be compared to the traditional frenectomy procedure in the comparator group. The level of the frenum will be measured at baseline and after 6 months. Pain scores will be recorded by the participants during the first week., conditionsModule conditions: High Frenum Attachment, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Randomized clinical trial. Allocation Ratio: 1:1, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, maskingDescription: Participants and outcome assessors will be unaware of the recruitment group. The allocation sequence will be contained within sequentially numbered, opaque, sealed packets that the patients will pull. According to the randomization table, the written number on the paper will allocate the patient to the intervention or control group., whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 46, type: ESTIMATED, armsInterventionsModule interventions name: Frenotomy, interventions name: Frenectomy, outcomesModule primaryOutcomes measure: Rebound / Relapse., secondaryOutcomes measure: Postoperative pain, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule locations facility: MSA University, status: RECRUITING, city: Giza, zip: 12566, country: Egypt, contacts name: Nada Zazou, role: CONTACT, phone: +201224016945, email: drzazou@hotmail.com, geoPoint lat: 30.00808, lon: 31.21093, hasResults: False
protocolSection identificationModule nctId: NCT06331312, orgStudyIdInfo id: CAIN457C22301E1, secondaryIdInfos id: 2023-508077-85-00, type: OTHER, domain: EU CT number, briefTitle: Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR), acronym: REPLENISH-EXT, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-10, primaryCompletionDateStruct date: 2028-03-13, completionDateStruct date: 2028-05-08, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: Novartis Pharmaceuticals, class: INDUSTRY, descriptionModule briefSummary: The purpose of this extension study is to assess the safety and tolerability of secukinumab when administered long-term in patients with polymyalgia rheumatica., conditionsModule conditions: Polymyalgia Rheumatica, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 300, type: ESTIMATED, armsInterventionsModule interventions name: Secukinumab, outcomesModule primaryOutcomes measure: Incidences of treatment emergent adverse events (AEs) and serious adverse events (SAEs), eligibilityModule sex: ALL, minimumAge: 50 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Novartis Investigative Site, status: RECRUITING, city: Parramatta, zip: 2150, country: Australia, geoPoint lat: -33.81667, lon: 151.0, hasResults: False
protocolSection identificationModule nctId: NCT06331299, orgStudyIdInfo id: BL013, briefTitle: A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer, acronym: UTOPIA, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-07, primaryCompletionDateStruct date: 2025-03, completionDateStruct date: 2026-03, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: UroGen Pharma Ltd., class: INDUSTRY, descriptionModule briefSummary: This Phase 3, single-arm, multicenter study will evaluate the efficacy and safety of UGN-103, a novel formulation of UGN-102, instilled in the urinary bladder of patients with low-grade non-muscle invasive bladder cancer (LG-NMIBC)., conditionsModule conditions: Bladder Cancer, conditions: Urothelial Carcinoma, conditions: Urothelial Carcinoma Bladder, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 87, type: ESTIMATED, armsInterventionsModule interventions name: UGN-103, outcomesModule primaryOutcomes measure: Complete response rate (CRR), secondaryOutcomes measure: Duration of response (DOR), secondaryOutcomes measure: Durable complete response (DCR) rate, secondaryOutcomes measure: Incidence of treatment-emergent adverse events (TEAEs), serious TEAEs, TEAEs of special interest, and abnormal clinical laboratory test results (hematology and serum chemistry), secondaryOutcomes measure: Mitomycin plasma concentrations, secondaryOutcomes measure: Mitomycin maximum plasma concentration (Cmax), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06331286, orgStudyIdInfo id: IIT20230091C-R1, briefTitle: The Effect of Dulaglutide as an Adjuvant Therapy on Cognitive Function in Bipolar Disorder Patients With Obesity, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-09-01, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: First Affiliated Hospital of Zhejiang University, class: OTHER, descriptionModule briefSummary: The primary objective of this study is to investigate the effect of dulaglutide adjuvant treatment in patients with bipolar disorder with obesity, in addition to exploring the effect of GLP-1RA on cognition of bipolar disorder., conditionsModule conditions: Bipolar Disorder, conditions: Obesity, conditions: Cognition, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: dulaglutide injection, outcomesModule primaryOutcomes measure: weight, primaryOutcomes measure: Concentration of blood glucose in blood, primaryOutcomes measure: Concentration of total cholesterol in blood, primaryOutcomes measure: Concentration of high density lipoprotein in blood, primaryOutcomes measure: Concentration of low density lipoprotein in blood, primaryOutcomes measure: Concentration of triglyceride in blood, primaryOutcomes measure: CBCT test results, secondaryOutcomes measure: 17-item Hamilton Depression Rating Scale (HAM-D17) Score, secondaryOutcomes measure: Treatment Emergent Symptom Scale (TESS) Score, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Department of Psychiatry, First Affiliated Hospital of Zhejiang University, status: RECRUITING, city: Hangzhou, state: Zhejiang, zip: 310000, country: China, contacts name: Hu ShaoHua, role: CONTACT, phone: 13957162903, email: dorhushaohua@zju.edu.cn, geoPoint lat: 30.29365, lon: 120.16142, hasResults: False
protocolSection identificationModule nctId: NCT06331273, orgStudyIdInfo id: CT2024-ZJU-OBS3, briefTitle: Impact of "No-touch" Technique on the Outcome of Liver Transplantation for Hepatocellular Carcinoma, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2028-04-01, completionDateStruct date: 2028-04-01, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: Zhejiang University, class: OTHER, collaborators name: Shulan (Hangzhou) Hospital, descriptionModule briefSummary: The "no-touch" technique has been one of the most important principles of oncological surgery and aimed to prevent seeding and tumor cell dissemination. Previous studies in hepatectomy have shown that no-touch technique surgery can reduce HCC recurrence and improve the survival of patients. However, there is no consensus on whether the no-touch technique in LT for HCC improves the outcomes. This study aims to prospectively include liver transplant patients from multiple transplant centers, collecting their pre-transplant clinical information, post-transplant pathological records and exploring and clarify the correlation between "no-touch" technique and the prognosis of LT patients., conditionsModule conditions: Liver Transplantation, conditions: No-touch Technique, conditions: Hepatocellular Carcinoma, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 800, type: ESTIMATED, armsInterventionsModule interventions name: Liver transplantation with "No-touch" technique, outcomesModule primaryOutcomes measure: Recurrence free surviavl rate, primaryOutcomes measure: Overall survival rate, primaryOutcomes measure: Tumor recurrence rate, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False